Atıf Formatları
TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

S. Gunalp Et Al. , "TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content," Frontiers in Immunology , vol.14, 2023

Gunalp, S. Et Al. 2023. TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content. Frontiers in Immunology , vol.14 .

Gunalp, S., Helvaci, D. G., Oner, A., Bursalı, A., Conforte, A., GÜNER, H., ... KARAKÜLAH, G.(2023). TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content. Frontiers in Immunology , vol.14.

Gunalp, Sinem Et Al. "TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content," Frontiers in Immunology , vol.14, 2023

Gunalp, Sinem Et Al. "TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content." Frontiers in Immunology , vol.14, 2023

Gunalp, S. Et Al. (2023) . "TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content." Frontiers in Immunology , vol.14.

@article{article, author={Sinem Gunalp Et Al. }, title={TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content}, journal={Frontiers in Immunology}, year=2023}